Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Maini

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Health Affairs (Project Hope)|May 6, 2024
Benefit Design And Biosimilar Coverage In Medicare Part D: Evidence And Implications From Recent ReformsLuca Bertuzzi, Luca Maini
Health Affairs Scholar|July 13, 2026
The effect of market size on pharmaceutical innovation: matching estimates to policy questionsLuca Maini, Mai Anh Tran, Josh Feng
Health Affairs (Project Hope)|November 3, 2025
Improved Insurance Coverage Increased Biosimilar Semglee's Market Share After The FDA's Interchangeability DesignationPragya Kakani, Bradley A Katcher, Luca Maini
Health Affairs Scholar|November 28, 2025
Savings from biosimilars and Medicare formulary accessKirsten Axelsen, Delphine Courmier, Ge Bai, et al.
Health Affairs (Project Hope)|October 7, 2024
Medicare Part D Protected-Class Policy Is Associated With Lower Drug RebatesPragya Kakani, Michael Anne Kyle, Amitabh Chandra, et al.
Health Affairs Scholar|May 15, 2026
Trends in prescription drug coverage restrictions in Medicare, Medicaid, and commercial insurance plans, 2011-2019Michael Anne Kyle, Pragya Kakani, Samantha L Burn, et al.
Health Affairs (Project Hope)|September 9, 2016
Has The Era Of Slow Growth For Prescription Drug Spending Ended?Murray Aitken, Ernst R Berndt, David Cutler, et al.
JAMA Health Forum|March 29, 2024
Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar CompetitionKimberly Feng, Massimiliano Russo, Luca Maini, et al.
The American Journal of Managed Care|November 10, 2023
Impact of including drug spending in oncology alternative payment modelsLuca Maini, Jacob P Klimek, David C Johnson, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Health Affairs (Project Hope)|May 6, 2024
Benefit Design And Biosimilar Coverage In Medicare Part D: Evidence And Implications From Recent ReformsLuca Bertuzzi, Luca Maini
Health Affairs Scholar|July 13, 2026
The effect of market size on pharmaceutical innovation: matching estimates to policy questionsLuca Maini, Mai Anh Tran, Josh Feng
Health Affairs (Project Hope)|November 3, 2025
Improved Insurance Coverage Increased Biosimilar Semglee's Market Share After The FDA's Interchangeability DesignationPragya Kakani, Bradley A Katcher, Luca Maini
Health Affairs Scholar|November 28, 2025
Savings from biosimilars and Medicare formulary accessKirsten Axelsen, Delphine Courmier, Ge Bai, et al.
Health Affairs (Project Hope)|October 7, 2024
Medicare Part D Protected-Class Policy Is Associated With Lower Drug RebatesPragya Kakani, Michael Anne Kyle, Amitabh Chandra, et al.
Health Affairs Scholar|May 15, 2026
Trends in prescription drug coverage restrictions in Medicare, Medicaid, and commercial insurance plans, 2011-2019Michael Anne Kyle, Pragya Kakani, Samantha L Burn, et al.
Health Affairs (Project Hope)|September 9, 2016
Has The Era Of Slow Growth For Prescription Drug Spending Ended?Murray Aitken, Ernst R Berndt, David Cutler, et al.
JAMA Health Forum|March 29, 2024
Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar CompetitionKimberly Feng, Massimiliano Russo, Luca Maini, et al.
The American Journal of Managed Care|November 10, 2023
Impact of including drug spending in oncology alternative payment modelsLuca Maini, Jacob P Klimek, David C Johnson, et al.
Pageof 1